|
Oncology Competitive Intelligence Leaders
Executive Summary: ONCrg analysts Kristen Cordova and Amber Mineo walk through the highest-impact lung cancer presentations from WCLC 2026 and preview what to watch at ESMO 2026 across small cell and non-small cell lung cancer, covering the context of each readout, how the treatment landscape is expected to shift, and the key questions the analyst team will be chasing.
Which mechanisms are commanding the late-breaker spotlight this year? Our analysts crunched the numbers across all LBAs:
ADCs lead the field — nearly a third of all LBA drugs, spanning NSCLC, breast, ovarian, and beyond.
Our oncology experts will be on the ground, analyzing the latest practice-changing clinical data, trial results, and emerging scientific insights as they unfold across over 20 tumor types.
Join our team as we break down the major readouts shaping thoracic oncology, including: 1L EGFR ex20ins+ NSCLC: First Phase III data for zipalertinib TKI-Naive ROS1+ NSCLC: Potentially registrational data for zidesamtinib 1L HER2m+ NSCLC: First Phase III data readout for T-DXd Relapsed SCLC: First CN Phase III data on two B7-H3 ADCs (tambotatug pelitecan […]
Our team will be tracking the latest breakthroughs and clinical updates shaping thoracic oncology. Planning your conference coverage or need strategic intelligence from WCLC? Start with our ONCrg planner. ONCrg is anticipating: • Data on novel therapies in NSCLC patient subsets with high unmet need: • First Phase III data for zipalertinib in 1L EGFR […]
Excerpt from Custom Post Type Indication: CVAC
Executive Summary: ONCrg analysts Robert Williams and Amanda Cook preview the highest-impact clinical presentations at ASCO 2026 across pancreatic, non-small cell lung, prostate, multiple myeloma, and NHL — covering the context of each readout, how the treatment landscape is expected to shift, and the specific signals the analyst team will be watching for on the floor.
Potential game changers: Late-stage readouts at ASCO/EHA: Selinexor: The last of the wave of novel MOA + ruxolitinib pivotal trials in frontline myelofibrosis (MF). All in this wave have faced struggles, selinexor included, with a missed symptom endpoint in Phase III SENTRY. Detailed outcomes reported at ASCO will inform not only the next steps for selinexor, but future development in the field of first-line MF as a whole.